AbbVie to strengthen production of immune disease drugs through Lando deal

AbbVie will buy drug developer Landos Biopharma for up to $212 million as the Humira maker seeks to expand its line of medicines to treat diseases related to the immune system, the companies said Monday.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM